TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05765539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: echOpen O1 Handheld Ultrasound device
Description: The performance of the Handheld ultrasound device (echOpen O1 device) will be assessed during these visits for all evaluation criteria.~* One examination with the US machine by the midwife focused on 4 targets ;~* One examination with a classic US machine by the same midwife (comparator) including the search for the four targets ;~* One examination with the US machine by a second operator ; Review of the images obtained by the US machine by the referring radiologist at a separate point of time.~The mode of delivery and the vital status of the mother and newborn will also be collected.~Operator A will start by using either the echOpen O1 device or the US machine (random order, via sealed envelopes) and will then perform the other type of examination.~Another operator (Operator B) will come to perform an examination with the Handheld ultrasound device (blind to the result of the first operator).~The switch between operators A and B will also be random.
Study: NCT05893849

Intervention type: DRUG
Intervention: Clinical probes
Description: Inpatients taking one or more clinical probes of CYP2C19 (omeprazole, rabeprazole, pantoprazole), CYP2D6 (metoprolol, carvedilol), CYP3A4 (rivaroxaban, finasteride, amlodipine, simvastatin), OAT (meropenem), OATP1B1 (atorvastatin, rosuvastatin) and OCT (metformin) will be included in the study.

Intervention type: DRUG
Intervention: Clinical probes
Description: Inpatients taking one or more clinical probes of CYP2C19 (omeprazole, rabeprazole, pantoprazole), CYP2D6 (metoprolol, carvedilol), CYP3A4 (rivaroxaban, finasteride, amlodipine, simvastatin), OAT (meropenem), OATP1B1 (atorvastatin, rosuvastatin) and OCT (metformin) will be included in the study.
Study: NCT05749614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine cream
Description: Group 1 was given 1 ml of 5% lidocaine cream on demand. They were instructed to apply the lidocaine cream evenly in a circular pattern to the glans penis without precise application to the sensitive area of the glans penis. The treatment lasted for a total of 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine cream
Description: Group 2 had a penile biological vibration threshold test performed to detect loci with a lower threshold. They were instructed to apply 1 ml of 5% lidocaine cream to the sensitive loci on the glans penis for 4 weeks.
Study: NCT06038331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SclerFIX-IP
Description: Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the STT joint
Study: NCT05103345

Intervention type: DRUG
Group type: OTHER
Intervention: SGN1
Description: SGN1,will be administered intratumorally,which dosage is 0.9-2.0×109 cfu /vial.
Study: NCT05707780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resin-matrix
Description: posterior crowns

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monolithic zirconia
Description: posterior crowns
Study: NCT06772506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)
Description: non-surgical technique plus splint and ultrasonic device with 200 mg Tetracycline

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Minimally invasive non-surgical technique with mini five and after five minimally invasive instrument plus splint
Description: minimally invasive instruments, with mini five and after five minimally invasive instrument ultrasonic scaler device, conventional radiographic device and periodontal instruments with post-operative 1 gram penicillin for 3 days regulatory Statement: This study does not include an FDA-regulated device intervention, as the tools utilized are not the subject of investigation but are instead employed as part of routine clinical
Study: NCT06772142

Intervention type: DEVICE
Group type: OTHER
Intervention: Peripheral Nerve Stimulation
Description: Peripheral Nerve Stimulation

Intervention type: DEVICE
Group type: OTHER
Intervention: Peripheral Nerve Stimulation
Description: Peripheral Nerve Stimulation
Study: NCT05707780

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metal-ceramic
Description: posterior crowns
Study: NCT05789017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone and Mycophenolate Mofetil
Description: Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone and Mycophenolate Mofetil
Description: Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Patients are treated with low dose mycophenolate (1-1.5g/day) during remission maintenance period for 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Patients are treated with leflunomide (20 mg/day) during remission maintenance period for 12 months.
Study: NCT04751162

Intervention type: DEVICE
Intervention: Actigraphy device (wearable) and mobile application
Description: Participants will be asked to wear an actigraphy device (wearable) and to install a mobile application on their smartphones (cf. Broderick et al., 2019) for tracking PA, SQ and symptoms for 3 weeks

Intervention type: DEVICE
Intervention: Actigraphy device (wearable) and mobile application
Description: Participants will be asked to wear an actigraphy device (wearable) and to install a mobile application on their smartphones (cf. Broderick et al., 2019) for tracking PA, SQ and symptoms for 3 weeks
Study: NCT05634759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin for Routine Community-wide MDA
Description: Oral azithromycin, also known as the brand name Zithromax®, is a macrolide antibiotic and is used in the treatment of active trachoma. The recommended dosage for the treatment of trachoma is a single dose of 20mg/kg of body weight and is implemented by a Age-height based dosing strategy for the trachoma MDA campaigns. Oral azithromycin can be administrated in either tablet form or powder for oral suspension (POS). Zithromax® is donated by Pfizer Inc through the International Trachoma Initiative (ITI) to the South Sudan Federal Ministry of Health to use in community-wide MDA throughout South Sudan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin for Routine Community-wide MDA
Description: Oral azithromycin, also known as the brand name Zithromax®, is a macrolide antibiotic and is used in the treatment of active trachoma. The recommended dosage for the treatment of trachoma is a single dose of 20mg/kg of body weight and is implemented by a Age-height based dosing strategy for the trachoma MDA campaigns. Oral azithromycin can be administrated in either tablet form or powder for oral suspension (POS). Zithromax® is donated by Pfizer Inc through the International Trachoma Initiative (ITI) to the South Sudan Federal Ministry of Health to use in community-wide MDA throughout South Sudan.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin for Routine Community-wide MDA
Description: Oral azithromycin, also known as the brand name Zithromax®, is a macrolide antibiotic and is used in the treatment of active trachoma. The recommended dosage for the treatment of trachoma is a single dose of 20mg/kg of body weight and is implemented by a Age-height based dosing strategy for the trachoma MDA campaigns. Oral azithromycin can be administrated in either tablet form or powder for oral suspension (POS). Zithromax® is donated by Pfizer Inc through the International Trachoma Initiative (ITI) to the South Sudan Federal Ministry of Health to use in community-wide MDA throughout South Sudan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two Additional Rounds of Azithromycin for Children
Description: An additional round of treatment will be given one week after the routine community-wide MDA, and a second additional round will be given two weeks later (3 weeks after the routine community-wide MDA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin for Second Community-wide MDA
Description: A second community-wide MDA will be given 6 to 8 months after the routine community-wide MDA. The timing of the second MDA will depend on local conditions and logistical concerns.
Study: NCT05980520

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taurine+corn starch+white sugar
Description: Taurine granules mixed with corn starch and white sugar, 0.4g in 1 bag, taken orally. One time dosage: 1 bag each time for 1-2 years old, 3 times a day, 1.5 bags each time for 3-5 years old, 3 times a day, 2 bags each time for 6-8 years old, 3 times a day, 2.5-3 bags each time for 9-13 years old, 3 to 4 bags each time for children and adults over 14 years old, 3 times a day. The use of taurine is strictly in accordance with the specifications of Chinese Pharmacopoeia.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn starch+white sugar
Description: 0.4g in 1 bag, taken orally. One time dosage: 1 bag each time for 1-2 years old, 3 times a day, 1.5 bags each time for 3-5 years old, 3 times a day, 2 bags each time for 6-8 years old, 3 times a day, 2.5-3 bags each time for 9-13 years old, 3 to 4 bags each time for children and adults over 14 years old, 3 times a day.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral rehabilitation therapy
Description: Structured training courses which included: visual arrangement, routine, environmental arrangement, program schedule, personal work system consists of five parts. The course is designed and implemented by qualified behavioral rehabilitators who have worked for more than 5 years, with the participation of parents. The daily training time is about 6-8 hours, and the total intervention time is not less than 40 hours per week.
Study: NCT06770049

Intervention type: BEHAVIORAL
Intervention: Standard Lifestyle Intervention (SLI) program
Description: Subjects will receive recommendations for calorie and macronutrient intake, physical activity, and behavioral skills to be followed for 12 months and will be delivered by a multidisciplinary team of obesity experts in a 12-month structured follow up. Participants will meet with a registered dietician as well as member of the study team to learn more about their intervention. Diets will be prescribed for each participant with a 30% calorie deficit calculated from measured REE. Macronutrient composition will be guided based on the patient preference. Participants will be prescribed 150 minutes of physical activity per week (spread across 4-5 days) and recommendations to reach 10,000 steps daily. During the first 12 weeks, participants will be scheduled a 12-week behavioral program focusing on self-monitoring and stimulus control using cognitive-behavioral approaches to promote adherence to diet and exercise prescriptions.

Intervention type: BEHAVIORAL
Intervention: Phenotype-tailored Lifestyle Intervention (PLI) program
Description: Subjects will receive recommendations for calorie and macronutrient intake, physical activity, and behavioral skills to be followed for 12 months and will be delivered by a multidisciplinary team of obesity experts. The recommendations will be determined a priori to tailor for each obesity phenotype
Study: NCT06770803

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Pressure Pneumoperitoneum
Description: The objective of this trial is to determine whether the maintenance of a low intraperitoneal insufflation pressure (IIP) of ≤10 mmHg during the parenchymal transection phase of conventional and robotic-assisted laparoscopic liver resection is non-inferior to a higher IIP of ≥14 mmHg in terms of intraoperative blood loss, gas embolisms, perioperative morbidity, and mortality.
Study: NCT05980520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral rehabilitation therapy
Description: Structured training courses which included: visual arrangement, routine, environmental arrangement, program schedule, personal work system consists of five parts. The course is designed and implemented by qualified behavioral rehabilitators who have worked for more than 5 years, with the participation of parents. The daily training time is about 6-8 hours, and the total intervention time is not less than 40 hours per week.
Study: NCT05841095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISA104
Description: SLP vaccine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution (0.9% NaCl)
Study: NCT05824754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Just-In-Time-Adaptive-Intervention (JITAI)
Description: Behavioral: MiWaves behavioral messages~Participants will be using the MiWaves mobile app for 30 days. When a participant is assigned to receive a message, a message will be randomly selected from a pool of intervention message sets. Messages are based in motivational interviewing and include affect management and behavioral economic strategies.
Study: NCT06032442

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ARTNEO
Description: Dietary Supplement: undenaturated collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)~Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.~Suggested Use: Adults, 1 capsule daily with meals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artra
Description: Active ingredients:~Glucosamine hydrochloride 500 mg Chondroitin sulfate sodium 500 mg~Excipients:~dibasic calcium phosphate, microcrystalline cellulose, croscarmellose sodium, stearic acid, magnesium stearate.~Orally; adults and children over 15 years of age are prescribed 1 tablet 2 times a day for the first three weeks; 1 tablet 1 time per day for the next weeks and months.
Study: NCT04887831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Trilaciclib administered IV prior to chemotherapy and avelumab maintenance therapy on each day chemotherapy and avelumab maintenance therapy is administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin administered IV on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered IV on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered IV on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered IV on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Avelumab will be dosed on Day 1 of each 14-day maintenance cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be dosed on Day 1 of each 14-day maintenance cycle
Study: NCT05999318

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active continuous Theta Burst Stimulation
Description: Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham continuous Theta Burst Stimulation
Description: Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
Study: NCT04696640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring
Description: Participants' glucose data will be monitored by the study team using population analytic reports. Participants who either have excessive hypoglycemia or hyperglycemia on these reports will be contacted by a pediatric endocrinologist (the principal investigator) to discuss any necessary adjustments to their home diabetes management plans. This intervention will be in addition to their usual care (regular visits at the UC Davis Pediatric Endocrinology clinic).
Study: NCT05048719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study: NCT05557760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training (CCT)
Description: The CCT training group without booster sessions will receive 10 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT). The aPASAT is a Cognitive Control Training where participants need to click on the sum of the last two heard digits.~Task difficulty is modified based on the participants' current task performance, allowing training of cognitive control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training (CCT) + Booster Sessions
Description: The CCT with booster sessions group will receive 10 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT). After these training sessions, participants in this condition will be asked to complete additional CCT sessions after reporting two consecutive assessments of increased depressive symptoms during the monitoring period (PHQ-9 scores equal or greater to 9). Specifically, they will then be instructed to perform three additional sessions within one week. This may be repeated when the participant reports multiple consecutive assessments of increased depressive symptoms during the post-training phase, with a minimum of 3 weeks between the booster sessions and a maximum of 9 boosters (3 x 3 sessions) in total.
Study: NCT05715112

Intervention type: PROCEDURE
Intervention: Graded Motor Imagery
Description: GMI consisting of education, sensory integration of the foot using contact, flooring samples, immersion, and two point discrimination.
Study: NCT05776095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyedeal® Model PX65AS1 IOL
Description: Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.
Study: NCT04708977

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-level lateral lumbar interbody fusion with Indirect Decompression
Description: One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-level lateral lumbar interbody fusion with Direct Decompression
Description: One-level lateral lumbar interbody fusion, with or without percutaneous posterior instrumentation. Thorough discectomy will be performed using lateral access instruments. Fusion will then be performed using lateral access interbody cage and allograft bone graft with or without use of recombinant human bone morphogenic protein 2.~Additionally, direct decompression through midline or parasagittal approach will be utilized. A unilateral laminotomy or complete bilateral laminectomy may be performed.
Study: NCT05546580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iadademstat
Description: iadademstat oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib Oral Tablet
Description: 120 mg Gilteritinib